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HIV/AIDS: Emerging threat to 
cardiovascular health in sub-Saharan 
Africa
To the Editor: Public health in sub-Saharan Africa (SSA) is at 
a crossroads owing to an increasing non-communicable disease 
burden, with a sizeable contribution from cardiovascular disease 
(CVD). CVD is the top cause of death globally,[1] and an estimated 
80% of CVD-related deaths occur in low- to middle-income coun-
tries, including South Africa (SA).[2] Although epidemiological 
transition is an important factor contributing to the rise in 
cardiovascular risk factors and CVD,[3] the emerging interaction 
between communicable diseases such as HIV/AIDS and CVD 
should not be neglected. HIV infection is now recognised as an 
independent cardiovascular risk factor; however, the data are 
mainly from developed countries.[4,5] 
The paucity of studies investigating this question in SSA, 
where demographic and socioeconomic realities, HIV strains and 
antiretroviral (ARV) guidelines are different, is of great concern. In 
high-income countries, HIV-related CVD manifests as coronary 
heart disease;[4] conversely, the incidence of coronary heart disease is 
believed to be relatively low in HIV-infected SSA populations.[6] Most 
reports cite pulmonary hypertension, cardiomyopathy and tuber-
culous pericarditis as the predominant HIV-related cardiovascular 
conditions.[6] A recent cross-sectional study in Soweto, SA, showed 
that only 2.4% of patients presenting with coronary heart disease for 
the first time were HIV-positive.[7] We believe that these and other 
findings may not represent the full picture or future trends of HIV-
related CVD in SSA. In recent years, data have started to emerge 
pointing to a high incidence of proatherogenic cardiovascular risk 
factors in HIV-infected participants, including hypertension, obesity, 
dyslipidaemia and endothelial activation.[5,8,9] Unfortunately the vast 
majority of these studies are observational, cross-sectional or hospital 
based, with no longitudinal follow-up. This hampers thorough 
assessment of the incidence and nature of cardiovascular risk and 
disease trajectories in people living with HIV/AIDS. Furthermore, 
HIV infection is inextricably linked with antiretroviral therapy (ART), 
another putative cardiovascular risk factor. It is well established that 
several ARV drugs can result in increased cardiovascular risk;[10] 
however, for as long as this possible link is not investigated in our 
context, serious future cardiovascular health challenges may arise, 
particularly in view of the massive ART roll-out programmes initiated 
in recent years.[6] 
In conclusion, we believe there is a real possibility that HIV 
infection and ART are emerging driving forces behind the rapidly 
increasing cardiovascular risk factor and CVD rates in SSA. If the 
lack of population studies investigating this question persists, public 
health services may be even less prepared for the multiple burden of 
disease facing the continent. 
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